PubRank

P E Thorpe

Author PubWeight™ 77.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997 2.59
2 Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000 2.07
3 Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998 1.78
4 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995 1.62
5 The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 1982 1.55
6 Percutaneous transthoracic needle aspiration biopsy: a comprehensive review of its current role in the diagnosis and treatment of lung tumors. Chest 1998 1.42
7 Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000 1.41
8 An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst 1985 1.37
9 Preparation of antibody-toxin conjugates. Methods Enzymol 1985 1.34
10 Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 2001 1.34
11 Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000 1.25
12 Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 2000 1.19
13 An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. Cancer Res 1988 1.18
14 Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. Eur J Biochem 1981 1.15
15 A new method for radiochemical separation of arsenic from irradiated germanium oxide. Appl Radiat Isot 2005 1.15
16 Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin. Nature 1978 1.14
17 Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol 1988 1.10
18 Vascular targeting--a new approach to the therapy of solid tumors. Pharmacol Ther 1994 1.08
19 Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993 1.08
20 Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur J Biochem 1985 1.07
21 Purification of ricin A1, A2, and B chains and characterization of their toxicity. J Biol Chem 1986 1.06
22 Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A 1993 1.06
23 Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2002 1.05
24 Upper extremity venous thrombosis. Case report and literature review. Orthop Rev 1990 1.05
25 Standing surgical repair of cystorrhexis in two mares. Vet Surg 1999 1.04
26 Expression of ricin A chain in Escherichia coli. FEBS Lett 1987 1.03
27 The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001 1.02
28 Microplate culture of mouse lymph node cells. I. Quantitation of responses to allogeneic lymphocytes endotoxin and phytomitogens. J Immunol Methods 1974 1.02
29 Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998 0.99
30 The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 1985 0.99
31 Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res 1991 0.98
32 The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol 1989 0.97
33 Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. Anal Biochem 1987 0.96
34 Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 1998 0.93
35 The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis. J Pathol 2001 0.93
36 Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment. Eur J Biochem 1980 0.91
37 Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 1987 0.91
38 Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS Lett 1990 0.90
39 Immunotoxins: magic bullets or misguided missiles? Trends Pharmacol Sci 1993 0.90
40 Immunotoxins containing ricin or its A chain. Semin Cell Biol 1991 0.89
41 Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. Br J Cancer 1988 0.87
42 Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody-ricin conjugate. Nature 1982 0.87
43 The removal of carbohydrates from ricin with endoglycosidases H, F and D and alpha-mannosidase. Biochim Biophys Acta 1985 0.87
44 A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992 0.87
45 Functional and morphological assessment of rat aorta stored in University of Wisconsin and Eurocollins solutions. Transplantation 1993 0.86
46 VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001 0.86
47 Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress. J Vasc Res 2004 0.86
48 Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein from Saponaria officinalis. Virchows Arch B Cell Pathol Incl Mol Pathol 1987 0.85
49 Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. J Thromb Haemost 2004 0.84
50 Phosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function. Parasite Immunol 2013 0.84
51 Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. Cancer Res 1988 0.84
52 In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997 0.83
53 Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. Eur J Biochem 1984 0.83
54 Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin. J Exp Med 1987 0.83
55 The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution. Biochim Biophys Acta 1987 0.82
56 Antibody toxin conjugates: a perspective. Prog Allergy 1988 0.81
57 Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-1 antibody-ricin conjugate. Br J Cancer 1985 0.80
58 Surgery for conditions causing decreased fertility in mares. Case selection. Vet Clin North Am Equine Pract 1988 0.80
59 Posttraumatic innominate artery aneurysm with occlusion of the common carotid artery at its origin by an intimal flap. Ann Vasc Surg 1993 0.80
60 Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. Cancer Drug Deliv 1986 0.80
61 TAT-BH4 counteracts Abeta toxicity on capillary endothelium. FEBS Lett 2007 0.80
62 Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Br J Haematol 1987 0.80
63 Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and non-parenchymal cells of rat liver. Biochim Biophys Acta 1985 0.80
64 Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. Cancer Drug Deliv 1985 0.79
65 Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. Clin Exp Immunol 1981 0.79
66 An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A. Blood 1984 0.79
67 Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. Biotechniques 2001 0.79
68 Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells. Biochim Biophys Acta 1996 0.78
69 Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. Biochim Biophys Acta 1988 0.78
70 Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins. Cancer Treat Res 1988 0.78
71 Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver. Cancer Treat Res 1988 0.78
72 Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochim Biophys Acta 1988 0.78
73 Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. Cancer Immunol Immunother 1991 0.77
74 Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model. Cell Biophys 1994 0.76
75 Circular dichroism of isolated ricin A- and B-chains. Biophys Chem 1988 0.76
76 Colovenous fistula complicating diverticulitis: CT and radiographic findings. Abdom Imaging 1997 0.76
77 Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. Br J Cancer 1988 0.75
78 Optimal conditions for the preservation of mouse lymph node cells in liquid nitrogen using cooling rate techniques. Cryobiology 1976 0.75
79 Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins. Scand J Rheumatol Suppl 1988 0.75
80 Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin. Behring Inst Mitt 1984 0.75
81 Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clin Exp Metastasis 2000 0.75
82 Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids. Int J Cancer 1995 0.75
83 Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model. Can J Physiol Pharmacol 1996 0.75
84 Effect of iodinated contrast media on neutrophil adhesion to cultured endothelial cells. J Vasc Interv Radiol 1998 0.75
85 Angiostatic therapy gets moving. Trends Cell Biol 1997 0.75
86 In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A. Haematol Blood Transfus 1987 0.75
87 A comparison of the in vitro and in vivo activities of conjugates of anti-mouse lymphocyte globulin and abrin. Biochim Biophys Acta 1982 0.75
88 A simple and rapid method for purifying the extracellular domain of human tissue factor. Thromb Res 1998 0.75
89 Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats. Haematol Blood Transfus 1983 0.75
90 The effect of abrin, anti-lymphocyte globulin and their conjugates on the immune response of mice to sheep red blood cells. Experientia 1981 0.75
91 Immunotoxins. Bioessays 1986 0.75
92 Chimeric proteins containing ricin A chain. Targeted Diagn Ther 1992 0.75
93 Endothelin-1 levels in ischaemia, reperfusion, and haemorrhagic shock in the canine infrarenal aortic revascularisation model. Eur J Vasc Surg 1994 0.75
94 Neuropeptide Y levels during ischemia and reperfusion in the canine infrarenal aortic revascularization model. Ann Vasc Surg 1994 0.75
95 A novel membrane-acting immunotoxin, the immunolysin, with therapeutic potential. Biochem Soc Trans 1992 0.75
96 Enzymic removal of two oligosaccharide chains from ricin B-chain. FEBS Lett 1986 0.75